Humira becomes first treatment approved for pyoderma gangrenosum

28 November 2020
humira_sign_large

US drugmaker AbbVie (NYSE: ABBV) and its Japanese marketing partner Eisai (TYO: 4523) on Friday announced approval of an additional indication of Humira (adalimumab), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (PG).

Humira, which is already the biggest-ever-selling drug in the world, was granted orphan drug designation for the treatment of PG in 2019. This indication counts for Humira's 12th indication in Japan and makes Humira the world's first drug indicated for the treatment of PG.

Clinical backing

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology